ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
41.69
+0.02 (0.05%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 41.16 - 42.02
52 week 19.21 - 46.48
Open 41.95
Vol / Avg. 433,901.00/923,072.00
Mkt cap 4.18B
P/E     -
Div/yield     -
EPS -1.15
Shares 100.30M
Beta 3.00
Inst. own 98%
Aug 3, 2015
Q2 2015 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 24, 2015
ACADIA Pharmaceuticals Inc at JMP Securities Life Sciences Conference - Webcast
Jun 15, 2015
ACADIA Pharmaceuticals Inc Annual Shareholders Meeting
Jun 2, 2015
ACADIA Pharmaceuticals Inc at Jefferies Global Healthcare Conference - Webcast
May 13, 2015
ACADIA Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 ACADIA Pharmaceuticals Inc Earnings Release
Apr 14, 2015
ACADIA Pharmaceuticals Inc at Needham Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1009375.00% -77062.50%
Operating margin -1013800.00% -77691.66%
EBITD margin - -77520.00%
Return on average assets -51.62% -35.94%
Return on average equity -54.47% -37.62%
Employees 119 -
CDP Score - -

Address

3611 Valley Centre Dr Ste 300
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Company’s drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinson’s disease psychosis, Alzheimer’s disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.

Officers and directors

Leslie L. Iversen Ph.D. Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Stephen R. Davis Interim Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Glenn F. Baity Executive Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Roger G. Mills M.D. Executive Vice President - Development, Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 60
Bio & Compensation  - Reuters
Stephen R. Biggar M.D., Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters
Michael T. Borer Independent Director
Age: 56
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 57
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Lester J. Kaplan Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters